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Vascularized composite tissue allotransplantation is a rapidly evolving area that has brought
technological advances to the forefront of plastic surgery, hand surgery, and transplant
biology. Composite tissue allografts (CTAs) may have profound functional, esthetic, and psy-
chological benefits, but carry with them the risks of life-long immunosuppression and the
inadequate abilities to monitor and prevent rejection. Allografts may suffer from additional
insults further weakening their overall benefits. Changes in local blood flow, lack of fully
restored neurologic function, infection, inflammation with subsequent dysregulated regen-
erative activity, and paucity of appropriate growth factors may all be involved in reducing
the potential of CTAs and therefore serve as new therapeutic targets to improve out-
comes. Strategies involving minimized immunosuppression and pro-regenerative therapy
may provide a greater path to optimizing long-term CTA function. One such strategy may
include mesenchymal stem cells (MSCs), which can provide unique anti-inflammatory and
pro-regenerative effects. Insights gained from new studies with MSCs on composite allo-
grafts, advances in tissue regeneration reported in other MSC-based clinical studies, as well
as consideration of newly described capacities of MSCs, may provide new regenerative
based strategies for the care of CTAs.
Keywords: composite tissue allotransplantation, tissue regeneration, mesenchymal stem cells, vascularized
composite tissue allotransplantation, cell therapy
OBSTACLES FACING VASCULARIZED COMPOSITE TISSUE
ALLOTRANSPLANTATION
Patients receiving life-saving solid organ transplants directly con-
trast with those considered for vascularized composite tissue allo-
transplantation (VCTA). In general,VCTA recipients are physically
healthy individuals except for the tissue defect; tissue transplan-
tation is not considered life-saving or life-prolonging (1). The
benefits of hand or face transplantation can include limb function
as well as improvements in psychological and social well-being.
A chronic immunosuppressive regimen may be needed to pre-
vent rejection of highly antigenic tissues of multiple embryonic
origins, including skin, muscles, and nerve is required (2). Rejec-
tion may not adequately present all the potential obstacles, which
serve to weaken the potential of these allografts; the regenerative
and repair capacity of the allograft must also be considered. Fac-
tors that impair tissue repair and regeneration in chronic wounds
and therapies that modulate these responses may also be con-
sidered for composite tissue allograft (CTA) survival. Endothelial
injury and corresponding changes in local blood flow, neuropathy,
infection, inappropriate inflammation, and paucity of appropriate
growth factors may all be involved in reducing the overall benefit
of CTAs and as a consequence, serve as new therapeutic targets
to improve composite allograft outcomes. While the risks of life-
long immunosuppressive therapy serve as the impetus for finding
alternative modulators of host immune responses to these trans-
planted allografts (3), focus will be directed toward regenerative
and reparative strategies, including those based on mesenchymal
stem cells (MSCs).
HAND COMPOSITE TISSUE ALLOTRANSPLANTATION
Since the first successful hand transplantation by Dubernard in
1998, over 70 hand composite tissue allotransplantations (HCTAs)
ranging from wrist level to shoulder level have been performed
around the world (4). The devastating loss of function after the
amputation of the upper extremity makes HCTA an appealing
method of restoration, as prostheses provide limited function-
ality. Plasticity of the human brain allows for cortical organi-
zation and adaptation after HCTA, with reversal of the cortical
organization shift that occurs after sensory and motor depri-
vation in amputees (5). Functionality post-hand transplant can
be evaluated using a 100-point functional score system, evaluat-
ing appearance (15 points), sensibility (20 points), motility (20
points), psychological and social acceptance (15 points), daily
activities and work status (15 points), and patient satisfaction
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and general well-being (15 points) (6). In a study of 38 HCTA,
all patients developed protective sensibility, 90% of patients had
tactile sensibility, and approximately 80% of patients had discrimi-
native sensation (7). Motor recovery, however, was not immediate;
intrinsic muscle function was observed between 9 and 15 months
post-transplantation. All patients were able to perform grasp and
pinch grip, hold small objects, turn door knobs, write, and work
(7). More than 85% were treated for acute rejection the first
year. Correspondingly, 63.6% were diagnosed with opportunis-
tic infections and 50% experienced metabolic complications of
immunosuppression including hyperglycemia, renal dysfunction,
hypertension, Cushing’s syndrome, and aseptic necrosis of the hip
with bilateral replacements. It is possible that, due to the num-
ber of events occurring during the earlier period post-transplant,
the mean functional scores tended to be lower in the first 4 years
(range 65.5–69, single hand transplant; range 60.5–82.5 bilateral
hand transplant) than the sixth and seventh years (88 points,
single hand; range 84.5–94 points, bilateral hand). These find-
ings suggest that while hand transplant provides a significant
advance in regained function, its early time course is plagued with
delayed function, potential tissue injury due to acute rejection, and
significant complications due to chronic immunosuppression.
In terms of long-term success, there are other, less well-
characterized variables which play a role. While cerebral plasticity
allows adaptation to use of the hands, it does not predict psy-
chological acceptance (8). Such acceptance may impact compli-
ance with post-transplant medication and the success of life-long
immunosuppressive therapy. Candidacy screening also presents
a recognized but less discussed variable in long-term success. In
the past year, in contrast to prior perception that hand transplant
recipients did not experience chronic rejection (7), new evidence
demonstrated, with devastating results, the effect of chronic rejec-
tion, originating with the endothelium. The amputation of the
Louisville hand patient ensued after the patient had received
substantive immunosuppression; Campath 1H induction (Alem-
tuzumab) was followed by tacrolimus and mycophenolate mofetil
maintenance therapy. The patient had three episodes of acute
rejection in the first 8 months characterized as a rash or slight
swelling and was treated with topical tacrolimus and/or steroids.
At 9 months, unmanageable ischemia secondary to severe inti-
mal hyperplasia, confluent in the donor arteries of the allograft,
resulted in amputation (9). Chronic rejection manifested as severe
obliterative intimal hyperplasia of the deep vessels of the arterial
tree, with the endothelium identified as a target of chronic rejec-
tion (9). The series of acute rejection preceding chronic rejection
and graft loss suggests that intervention during the early course
of the transplant mitigating or eliminating repetitive endothelial
injury may improve long-term results. Additionally, it is plausible
targeted therapeutics which provide pro-regenerative strategies for
the endothelium may offset or reduce manifesting cardinal events
that precipitate chronic rejection.
FACE COMPOSITE TISSUE ALLOTRANSPLANTATION
The first partial face allotransplantation was achieved in 2005 by
Dubernard in Amiens, France, and the first full face allotransplan-
tation, containing soft tissue and bony structures, was performed
in 2010 by Barret in Barcelona, Spain (10, 11). To date, over
20 facial allotransplantations with increasing comprehensiveness
have been performed thus far in France, USA, Spain, and China.
Face composite tissue allotransplantation (FCTA) furnishes the
perfect match in facial texture, pliability, and color, as well as
mimetic of function (12). While the lack of a suitable autolo-
gous substitute serves as a driving force behind FCTA, significant
challenges include control of infection, prevention of rejection,
psychological adaption, rehabilitation, cortical integration, and
ethical practice (13).
The face plays a major role in an individual’s interaction with
the outside environment. The face represents sense-of-self and
identity. In addition to the senses (smelling, hearing, etc.), it con-
veys emotion (smiling, kissing) and plays a major role in basic
physical functions (swallowing, breathing) (14). Facial disfigure-
ment or loss of motor and sensory function has devastating psy-
chological and social impact on an individual and FCTA manifests
as a utopia for restoration (15). However, the high visibility of the
face and its intimate relationship with the individual serves as a
source of controversy, with ethical considerations in face donation
and the donor’s family. Concerns that face transplant represents
an identity exchange or that the face of a loved one would be rec-
ognizable in a stranger impart an emotive barrier to FCTA (16,
17). Related challenges arise in the recipient with psychological
adaption, rehabilitation, and cortical integration.
Like hand transplant, neurologic sensory function precedes
motor function. Reestablishing sensation and motion for speech,
swallow, and mimicry through coaptation of the sensory and
motor nerves (trigeminal and facial nerves, respectively) remain
challenging. Near normal sensory recovery of the early cases has
been demonstrated between 3 and 8 months postoperatively by
quantitative sensory tests (18). Motor recovery has been slower
with limited published objective data on motor recovery; though
the first four patients were able to eat, drink, and speak within
7–10 days after transplantation (14). Functional MRI and elec-
tromyographic studies have been suggested as an objective tool to
determine motor recovery in FCTA (19).
Unlike hand transplantation, facial transplantation must over-
come the added hurdle of host responses directed against the
transplanted mucosal barrier and associated microbiome (2, 20,
21). Much like intestinal and lung transplants which establish
donor derived cellular barriers and associated microbiomes in
the transplanted host, the balance between diagnosis of infection
and rejection is likely to be equally problematic. So far, rates of
infection compared to solid organ transplantation have been less.
This observation may reflect the overall good health of the recipi-
ent prior to transplant (17), the low numbers transplanted, or an
incomplete ability to differentiate infection from rejection. Alter-
natively, a sub-population of face transplant recipients, severely
burned patients, may experience higher risk of both infection and
rejection due to their proclivity for developing sepsis (17). Infec-
tion and tissue damage has been noted to associate with poorer
graft outcomes (22).
Even with an ever-increasing number of FCTAs being per-
formed, consternation still remains over the unexpected death of
the world’s second face transplant recipient (China) and the death
of the world’s first concomitant hand and FCTA patient (France).
In 2009, Lantieri transplanted the upper 2/3 of face and bilateral
Frontiers in Immunology | Alloimmunity and Transplantation July 2013 | Volume 4 | Article 188 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antony et al. CTA, tissue regeneration, and MSC
hands to a 37-year-old recipient with significant burns. No acute
rejection episodes occurred but the patient suffered multiresis-
tant Pseudomonas aeruginosa infection on post-operative day 15
with destructive soft tissue infection, and subsequent death 65 days
after transplant due to anoxic cardiac arrest from tracheostomy
obstruction in the context of septic complications (23). This most
recent death has spurred new questions regarding the appropriate-
ness of concomitant face and hand tissue (CFHT) allotransplan-
tation, stemming from length of procedure, cortical integration,
antigenic load, and safety in burn patients who often undergo
presensitizing events such as temporary cadaveric skin allograft
coverage or blood transfusions (24, 25) and retain indolent, resis-
tant bacteria which can reemerge in a clinically significant manner
during systemic immunosuppression (26).
CURRENT IMMUNOSUPPRESSIVE STRATEGIES
Original work involving cyclosporine A and successful rat hind-
limb allotransplantation have paved the way for modern immuno-
suppressive therapy for composite tissue allotransplantation (27).
Immunosuppressive protocols applied in VCTA are derived from
those used in solid organ transplantation using triple-drug reg-
imens (7). Following the guidelines established by Petruzzo et
al. (7), the majority of VCTA patients began immunosuppres-
sive induction therapy for T-cell depletion using either the poly-
clonal anti-thymocyte globulin (ATG) antibody or the monoclonal
antibodies directed against CD25 (basiliximab) or CD52 (Cam-
path1/alemtuzumab), followed with immunosuppressive main-
tenance therapy accomplished using a triple-drug cocktail of
tacrolimus, mycophenolate mofetil, and steroids. Acute rejec-
tion episodes are treated with adjustment in steroid or a short
course of steroid or induction agent, and use of topical tacrolimus
and steroid (7). More recently, steroid reduction/avoidance and
conversion of tacrolimus to sirolimus for long-term therapy
(improved renal function) has been applied (28).
In addition to triple therapy, some centers have attempted
novel methods to reduce immunosuppression requirements.
Devauchelle and Dubernard included bone marrow donor infu-
sion in the first case, anticipating improved survival in recipients
of solid organ transplant and donor hematopoietic stem cells (29,
30). However, no benefit was seen. Hivelin et al. (31) and Lantieri
et al. (23) later introduced extracorporeal photopheresis to face
transplantation to reverse rejection crises by viral infection.
Decreasing the risk profile of CTA requires eliminating or
reducing the obligatory life-long immunosuppression compo-
nent. Induction of donor-specific immunologic tolerance has been
proposed in various clinical and animal models. The Pittsburg
Hand Transplant Program has found early benefit with donor bone
marrow transfusion at day 15, with reduction in immunosuppres-
sive burden (maintenance with oral tacrolimus versus triple ther-
apy) (21) though long-term results are pending. Immunotolerance
is a goal for organ and composite tissue transplantation, though
particularly relevant for CTA, where procedures are not considered
life-saving. Kawai demonstrated donor-specific immunotolerance
across major histocompatibility complex barriers using a con-
ditioning regimen of cyclophosphamide, anti-CD2 monoclonal
antibody, thymic irradiation, and cyclosporine A before a com-
bined bone marrow and kidney transplant in HLA haplotype
mismatched living-related donor. Cyclosporine A immunosup-
pression was tapered over the next several months (in four of
five patients) with maintenance of stable renal function with-
out immunosuppression to date. Transient lymphohematopoietic
mixed chimerism without chronic rejection was observed (32).
Progressive steps in achieving stable mixed chimerism with
a non-myeloproliferative conditioning regimen and donor
hematopoietic stem cell infusion (33) have been achieved in lab-
oratory models, but clinical application is limited by the need
for donor preconditioning (26). Tolerance induction through the
establishment of mixed chimerism seems to require engraftment
of donor hematopoietic stem cells in the recipient bone mar-
row compartment (26). Engrafted stem cells facilitate central and
peripheral tolerance, by providing a persisting source of donor
cells. Recent studies have identified novel approaches with cotrans-
plantation of MSCs in addition to bone marrow transplantation
(34) or cotransplantation of polyclonal T-regulatory cells with
fully mismatched allogeneic donor bone marrow (35) to reduce
the toxicity of the conditioning regimen while enhancing CTA
survival. More recently, treatment with MSCs combined with pre-
operative irradiation and short term cyclosporine A, but without
bone marrow transplantation, has contributed to prolonged com-
posite tissue allotransplantation survival in a heterotopic hind-
limb swine model (36). Current clinical translation is impeded
by the lack of feasible protocols devoid of cytotoxic condition-
ing (e.g., irradiation and cytotoxic cells/mAbs). These treatment
algorithms offer potential realization of long-term multilineage
chimerism with graft tolerance.
MESENCHYMAL STEM CELLS IN SOLID ORGAN
TRANSPLANTATION
There is already strong preclinical and clinical indication for
the use of MSCs in solid organ transplantation suggesting this
approach could be beneficial inVCTA. In preclinical models, MSCs
have not only been shown to limit the extent of injury follow-
ing renal ischemia-reperfusion (37) but also demonstrated the
ability to prevent rejection in a mouse model of semiallogeneic
heart transplantation and a in a model of fully allogeneic islet cell
transplantation (38). Additionally, MSC are capable of promot-
ing a state of tolerance after cardiac allograft transplantation and
kidney transplantation (39, 40). While there is some preclinical
data suggesting that pretreatment with allogeneic MSCs may actu-
ally be detrimental to solid organ transplant by accelerating graft
rejection (41), graft rejection in this study occurred at the same
time when pretreated with MSCs as compared to their non-MSC-
treated controls. While MSC-treated animals showed increased
cellular and molecular markers for acute rejection as well a decline
in functional markers, overall rejection levels, and timing were not
affected by MSC pretreatment. It is unclear if this study’s find-
ings represent unique findings or are a result of differences in
immunosuppression and technical approaches as the majority or
preclinical work shows great promise for MSC as a therapeutic
agent. Currently, Phase I/II clinical studies are underway to deter-
mine the efficacy of MSC therapy in solid organ transplantation
(42–44).
Another benefit to using MSCs is the opportunity to
capitalize on the growing body of literature supporting the
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non-immunogenic properties of these cell populations. One key
obstacle in solid organ transplantation is the need for a donor-
recipient crossmatch. There is currently a large set of data sug-
gesting that MSCs are non-immunogenic (45–47) thereby making
the need for a crossmatch unnecessary. However, while these stud-
ies demonstrate the apparent immune-privileged nature of MSCs,
some recent studies (48, 49) have shown the presence of anti-
donor immune responses (T-cell and B-cell/antibody) following
in vivo transplantation of allogeneic MSCs. These more recent data
question both the concept that MSCs are truly immune-privileged
and the reality of non-crossmatched allogeneic MSC transplanta-
tion. While it is clear that further investigation is necessary to fully
understand the immunogenicity of MSCs, the potential to utilize
MSCs as an “off the shelf” therapeutic agent cannot be overlooked
and may offer a significant advantage in the setting of VCTA.
Because of increasing evidence to support beneficial effects of
MSC, extension of MSC therapy from solid organ transplantation
to VCTA is an appropriate next step for therapy in improving
outcomes in CTAs. Beyond potential for facilitating immuno-
tolerance, MSC application may potentiate therapeutic effects of
repair and regeneration to those reported in acute and chronic
wound models as VCTA contain skin elements, in contrast to solid
organ allografts, which would benefit from accelerated closure,
granulation, and angiogenesis.
VCTA AND SKIN MODELS (CHRONIC WOUNDS, FETAL
WOUNDS)
In VCTAs that include skin components, an effective progression
through the phases of inflammation, tissue formation, and remod-
eling must occur since these are the overlapping phases of skin
regeneration (50). Neutrophil and macrophage infiltration are
necessary prerequisites to regeneration since their absence leads to
deranged healing, chronic wounds with persistent inflammatory
responses and associated collateral tissue destruction.
Tissue injury typically results in the secretion of several medi-
ators of wound healing, such as platelet-derived growth factor,
which attract and activate macrophages and fibroblasts (51). MSC-
based therapies modulating neutrophil and macrophage responses
hold potential for targeted therapies in VCTA. To date, MSC
treatment of acute and chronic wounds results in more rapid
epithelialization, granulation tissue formation, and angiogenesis.
MSC differentiation to endothelial, keratinocyte, and pericyte cel-
lular types in cutaneous wounds has been observed despite low
engraftment efficiency (52).
The perspective of the VCTA as a chronic wound is based
on similarities seen in tissue dysregulation and potential pro-
regenerative synergistic targets that may act as counteragents
to retarded repair mechanisms in the setting of: (1) inflam-
mation, (2) macrophage-mediated inflammatory processes, (3)
impaired epithelialization and attenuated matrix deposition, and
(4) endothelial injury and intimal hyperplasia. All of these
processes serve as potential targets for MSC-based therapy, due
to the effect of MSCs on cytokine signaling pathways regulating
immune responses and inflammation.
Mesenchymal stem cell-potentiated tissue regeneration and
repair responses in chronic wound healing that may be paral-
leled and exploited in VCTA include: (1) MSC signaling with
enhancement of cellular responses including cell survival, pro-
liferation, migration, and gene expression; (2) MSC-conditioned
media exhibiting paracrine activity as a chemoattractant recruiting
macrophages and endothelial cells to the wound, including epi-
dermal keratinocytes and dermal fibroblasts (53); (3) downstream
effects of MSC signaling with reduced duration of inflammation
with promotion of phagocytosis and macrophage modulation
from pro-inflammatory to pro-regenerative; and (4) appropri-
ate matrix deposition with enhanced repair and regeneration of
endothelium. In this vein, MSC-based repair and regeneration in
adult injury can be compared and contrasted with fetal wound-
ing models which exhibit rapid re-epithelialization and “scarless”
healing.
Fetal healing serves as an ideal model for wound repair. Pluripo-
tent MSCs have been touted as the adult cellular proxy to reenact
the tissue regenerative capacity seen early in development. Despite
improved wound regeneration orchestrated by MSCs, there is
no substantial evidence that MSCs promote “scarless” healing
seen in fetal tissues mechanism due to MSC differentiation to
replace damaged skin (52). Fetal wounds are rich in metallopro-
teinases and display reduced levels of transforming growth factor
β1 (TGF-β1), which may serve as the basis behind scarless heal-
ing (50). Thus, many distinct signaling pathways act in concert to
achieve scarless healing. MSC-based alteration of cellular activity
via paracrine signaling may produce analogous effects and bear an
important role in potentiating wound repair and regeneration and
enhanced tissue survival. The remainder of this review will focus
on aspects of MSC which can be exploited to promote long-term
survival of VCTAs.
PROSPECTS OF MESENCHYMAL STEM CELLS IN VCTA
While a great deal of research has focused on immunosuppressive
strategies following VCTA, very little has focused on promoting
regeneration of the allograft components. Such a strategy, in com-
bination with immunosuppressive regimens, may improve early
function and reduce immunosuppressive requirements. Induction
of MSC differentiation into many of the components of VCTAs,
has been reported to induce significant regenerative effects on tis-
sues (54). However, low survival and proliferation rates of MSCs at
tissue injury sites have been observed, indicating that the regener-
ative effects of MSCs are not derived mainly from engraftment and
differentiation, but rather paracrine signaling mechanisms (52).
Since MSC-based regenerative properties are likely not due to
terminal differentiation, with several studies have demonstrated
that the number of MSCs administered could not numerically
account for all the components of regenerating tissue (55–58)
MSC-based signaling pathway modulation offers the greatest
potential for enhanced regeneration and repair in VCTA (52).
MSCs appear to provide their greatest regenerative effects through
paracrine regulation of multiple cell types. Secreted molecules by
MSCs attract macrophages, endothelial cells, keratinocytes, and
dermal fibroblasts to wounds in addition to stimulating increased
cellular function of these cells. This serves to not only reduce
the duration of inflammation and promote phagocytosis of tis-
sue debris, but it also induces appropriate matrix deposition,
promotes the repair and regeneration of endothelium, switches
macrophages from pro-inflammatory to pro-regenerative, and
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provide anti-microbial effects. On close evaluation of wound
histology, MSCs accelerate granulation tissue formation, epithe-
lialization, and angiogenesis (52). This enhanced tissue repair can
also be seen with application of MSC preconditioned medium
alone (37, 53, 59), demonstrating significant benefit from MSC-
secreted signaling factors without the additive advantage of MSC
pluripotency as the basis for regeneration.
Multiple strategies have been investigated to increase MSC pres-
ence at wounds, including the recruitment of endogenous MSCs as
well as the direct application of MSCs to the wound. The total ben-
efit derived from direct application of MSCs is additive with the
potential for regeneration coming through both cellular engraft-
ment and differentiation – exploiting MSC “stemness” – in addi-
tion to repair via paracrine signaling. Another strategy involves
signaling endogenous MSCs to mobilize from the bone marrow
and preferentially deposit in injured tissue over the surround-
ing, uninjured tissue (60–62). While the signaling mechanism
promoting the trafficking of MSCs to skin/wounds are not fully
understood at this time, chemokines SLC/CCL2 and substance
P have been implicated in recruitment and circulation (52, 63,
64). These modalities of increasing MSC-potentiated effects can
be paralleled into VCTA for enhanced regenerative capacity and
cellular survival through improved engraftment efficiency in addi-
tion to observed paracrine-mediated responses in wound models.
Overall increased potency and resilience of transplanted allografts
may result from improved early graft function with MSC-enacted
reduction of macrophage-derived inflammation, stimulated pro-
regenerative responses with enhanced epithelialization and wound
healing, and improvement in endothelium regeneration.
CONCLUSION
While the risks of life-long immunosuppressive therapy serve as
the impetus for finding alternative modulators of host immune
responses in VCTA, MSCs may offer novel reparative and regener-
ative based strategies with application in these transplanted allo-
grafts. Components of tissue dysregulation involving the endothe-
lial injury, delayed epithelialization, inappropriate inflammation,
and paucity of appropriate growth factors may all be involved in
reducing the overall benefit of CTAs and as a consequence, serve as
novel therapeutic targets for MSCs to improve allograft outcomes.
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